News | June 04, 2022
RH Capital announces investments to improve women’s health
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
